$ACT Headlines UK drug rejection, patent concerns take a

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$ACT Headlines

UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - blogs.marketwatch.com
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Staples awash in red; eBay up as Icahn posts new letter 4:09 p.m. March 6, 2014 - Victor Reklaitis
Icahn Enterprises reports profit up 144% in 2013 10:22 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 11:12 a.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 4:45 p.m. Feb. 24, 2014 - Victor Reklaitis
U.S. stock market is starting to ride a tech M&A wave 5:31 a.m. Feb. 24, 2014 - Wallace Witkowski
Actavis continues hot streak with better-than-expected earnings 11:21 a.m. Feb. 20, 2014 - blogs.marketwatch.com
Actavis swings to loss on charges, write-downs 8:03 a.m. Feb. 20, 2014 - MarketWatch.com
Pharma megamergers bring higher profits, better returns, study says 1:59 p.m. Feb. 19, 2014 - blogs.marketwatch.com
Actavis, Forest shares continue their climb in aftermath of $25 billion deal 11:03 a.m. Feb. 19, 2014 - blogs.marketwatch.com
U.S. stocks edge up; Nasdaq gains for 8th day in a row 4:38 p.m. Feb. 18, 2014 - Anora Mahmudova
Forest Laboratories, Actavis surge on buyout deal 4:10 p.m. Feb. 18, 2014 - Ben Eisen
S&P 500, Nasdaq extend win streaks but Dow dips: stock market live blog recap 4:06 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Forest buyout may not spell the end of dealmaking for Actavis 3:00 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Pharma ETFs pop on the Actavis-Forest deal 2:07 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Investors drive up price of Actavis-Forest deal 11:14 a.m. Feb. 18, 2014 - blogs.marketwatch.com
Actavis shares jump 7.8% on Forest Lab deal 9:35 a.m. Feb. 18, 2014 - Sue Chang
U.S. stock futures trim rise; Forest Labs soars 9:14 a.m. Feb. 18, 2014 - Sara Sjolin


Veteran Investor's Top Biotech and Drug Stocks 7:57 a.m. Today - Barrons.com
Should You Buy Actavis? 6:28 p.m. March 18, 2014 - GuruFocus.com
Actavis Prescribes Profits via M&A and Generic Drugs 8:27 p.m. March 16, 2014 - InvestorPlace.com
Actavis, Mylan to Benefit from Celebrex Ruling - Analyst Blog 5:20 p.m. March 14, 2014 - Zacks.com
Horizon Pharma Banks On Two-For-One Arthritis Drugs 1:05 p.m. March 14, 2014 - Investors Business Daily
Why Teva May Be Back From the Dead 10:07 a.m. March 14, 2014 - 247WallSt.com
Teva Pharmaceuticals Stock Could Rise 30% 12:54 a.m. March 14, 2014 - Barrons.com
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog 6:00 p.m. March 13, 2014 - Zacks.com
Narrower-than-Expected Loss at Supernus - Analyst Blog 9:40 a.m. March 13, 2014 - Zacks.com
Pfizer Says Court Invalidates Celebrex Patent 7:51 a.m. March 13, 2014 - The Wall Street Journal Interactive Edition
Pfizer Loses Patent On Celebrex, Plans To Appeal 2:59 p.m. March 12, 2014 - Investors Business Daily
Icahn Makes Case to eBay Investors 2:32 p.m. March 12, 2014 - The Wall Street Journal Interactive Edition
Greenberg: What You May Have Missed 9:33 a.m. March 12, 2014 - TheStreet.com
Will Horizon Pharma Spike Again On Quarterly Report? 7:02 a.m. March 12, 2014 - Investors Business Daily
How To Invest: Seek Stock Ideas In Sector Leaders 4:23 p.m. March 11, 2014 - Investors Business Daily
Actavis PLC (ACT): Today's Featured Drugs Laggard 5:01 p.m. March 10, 2014 - TheStreet.com
3 Stocks Underperforming Today In The Drugs Industry 1:04 p.m. March 10, 2014 - TheStreet.com
Forest Labs/Adamas Seek FDA Approval - Analyst Blog 5:00 p.m. March 7, 2014 - Zacks.com
Highflying Drug, Biotech Stocks Take Rare Drubbing 4:49 p.m. March 7, 2014 - Investors Business Daily
Columbia Labs buys back shares 9:30 a.m. March 7, 2014 - Seeking Alpha


New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus 8:00 a.m. March 13, 2014 - PR Newswire - PRF
Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit 5:35 p.m. March 12, 2014 - PR Newswire - PRF
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis 6:50 a.m. March 7, 2014 - PR Newswire - PRF
Actavis to Present at Barclays Global Healthcare Conference 8:00 a.m. March 4, 2014 - PR Newswire - PRF
Actavis Confirms Generic Colcrys® Patent Challenge 4:05 p.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Confirms Generic Multaq® Patent Challenge 8:00 a.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013; Non-GAAP EPS Increases 99% to $3.17 7:00 a.m. Feb. 20, 2014 - PR Newswire - PRF
Actavis to Present at Citi's 2014 Global Healthcare Conference 4:25 p.m. Feb. 19, 2014 - PR Newswire - PRF
Critical Alerts For Actavis, athenahealth, Seattle Genetics, JP Morgan Chase, and SodaStream Released By InvestorsObserver 9:31 a.m. Feb. 19, 2014 - PR Newswire - PRF
Actavis to buy Forest Labs for $25B and GT Advanced Tech acquires exclusive rights from Kyma Tech 12:31 a.m. Feb. 19, 2014 - ACCESSWIRE
Acquisition of Forest Laboratories, Inc. by Actavis plc May Not Be in Shareholders' Best Interests 9:02 p.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Cancel Q4 and FY 2013 Earnings Call Previously Scheduled for Thursday, February 20, 2014 5:13 p.m. Feb. 18, 2014 - PR Newswire - PRF
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Forest Laboratories, Inc. Stockholders 5:01 p.m. Feb. 18, 2014 - BusinessWire - BZX
Fitch Affirms Actavis at 'BBB-' on Forest Labs Acquisition; Outlook Stable 2:52 p.m. Feb. 18, 2014 - BusinessWire - BZX
FOREST SHAREHOLDERS NOTICE:Johnson & Weaver, LLP Announces Investigation of the Forest Laboratories, Inc. Proposed Acquisition by Actavis plc 9:43 a.m. Feb. 18, 2014 - BusinessWire - BZX
INVESTOR BUYOUT ALERT - Offer to Acquire Forest Laboratories - Shareholder Rights Law Firm Tripp Levy PLLC Seeks Higher Price And More Information For Shareholders 8:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction 7:00 a.m. Feb. 18, 2014 - PR Newswire - PRF
Actavis to Host Fourth Quarter 2013 Earnings Conference Call and Webcast 8:00 a.m. Feb. 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Treanda® Patent Challenge 8:00 a.m. Feb. 4, 2014 - PR Newswire - PRF

Scroll down for more posts ▼

Top 10 Most Recent News Articles

McKinley Irvin Earns Top 2027 Rankings in Family Law

Updated Category News Views 103

A Legal Eagle Soars High in 2027 Oh, the legal world can be as cutthroat as the stock market some days, especially when you're gunning for those top-tier rankings. This year, McKinley Irvin has managed to ruffle a few feathers in the Pacific Northwest, claiming top honors in the 2027 Best Law Firms rankings. And let me tell you, this wasn’t just handed to them on a...

Continue Reading
Koppers Navigates Q3: Margins Squeeze Amid Growth

Updated Category News Views 123

Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...

Continue Reading
West Virginia Water Gains: Central Grove Upgrade Begins

Updated Category News Views 118

Kickoff at Central Grove: What’s Brewing? Ever wander through Kearneysville, W.Va., and wonder what’s going on with that bustling crew near Goldenrod Drive? The folks at West Virginia American Water have kicked off groundwork for the much-anticipated Central Grove Water Treatment Plant. This, comrades, isn’t just some shiny new shed we’re talking about. Oh no,...

Continue Reading
Soligenix Holds Steady Amidst Shifting Financial Landscape

Updated Category News Views 53

Stepping into Soligenix's News Every time Soligenix pops up on the radar, it feels like we're watching a biopharma soap opera. This time, they're juggling updates and quarterly numbers that scream both promise and peril. The New Jersey-based company, known for its focus on niche markets with unmet medical needs, tossed out some shiny clinical developments alongside a...

Continue Reading
Lilly's Digital Healthcare Push with Hims & Hers

Updated Category News Views 194

Revolutionizing Access: Pharmaceuticals Meet Telehealth In an era where digital disruption is shaking every sector, Eli Lilly (NYSE:LLY) isn't sitting idle. They've just forged a partnership with Hims & Hers (NYSE:HIMS), one that's diving headfirst into the telehealth revolution. We're talking a slick merger of pharmaceuticals and digital platforms—offering FDA-approved...

Continue Reading
Pinterest Faces Legal Probe: Investor Concerns Rise

Updated Category News Views 43

Legal Storms Gather on Pinterest's Horizon I remember a time when Pinterest was the darling of Wall Street, but here we are, staring at an investigation that's got more layers than an onion. On November 6, 2026, news broke that Kahn Swick & Foti, LLC (KSF) is sniffing around Pinterest's officers and directors. This is no small fry since KSF is steered by none other than...

Continue Reading
CorelDRAW's Flexibility: A Designer's One-Time Buy?

Updated Category News Views 87

CorelDRAW: A Design Powerhouse Without Recurring Bills? Every so often, a software option comes along that piques my interest, and right now, it's CorelDRAW Graphics Suite. Consumer365 has shone a light on this nifty tool for its one-time purchase model—a breath of fresh air in the age of endless subscriptions that seem to drain more than enthusiasm as the months roll...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 167

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading
NovoTech Climbs Charts: Chambers USA Spotlight Kudos

Updated Category News Views 125

NovoTech's Moment in the Spotlight Every once in a while, a small fish manages to swim with the sharks and come out shining. NovoTech, a relative newcomer in the swarm of patent law firms, has snagged itself a spot in the inaugural Chambers USA Spotlight 2027 DC Metro Guide. Considering they're playing in the bustling intellectual property scene, this is no small...

Continue Reading
Innodisk's Q3 Revenue Surges 579.9% Boosting AI Growth

Updated Category News Views 78

Innodisk's Skyrocketing Financial Surge Imagine raking in a revenue leap of 579.9% year-over-year. Yep, that's what Innodisk—a major player from Taiwan in industrial memory, storage, and edge AI solutions—just reported for Q3. I'll go out on a limb here and say that doesn't happen every day. Key Numbers That Paint the Big Picture Let’s dive into those digits. We're...

Continue Reading

Top 5 Most Recently Viewed Articles

W3.io Secures $7M to Enhance Web3 Usability and Growth

Updated Category News Views 288

W3.io Secures Funding to Transform Web3 Landscape Web3 has limitless potential, yet its adoption has faced significant barriers. The fragmented and complex infrastructure proved to be a challenge, leading to a bottleneck in usability. This reality is what prompted W3.io to take a proactive stance. W3.io, spearheaded by a groundbreaking coalition of innovators,...

Continue Reading
Linqto's Innovative Platform Enhances Private Market Access

Updated Category News Views 123

Democratizing Private Investing with Linqto Linqto, a pioneer in financial technology, is reshaping the landscape of private investing. They are committed to making investments in private companies and startups accessible to individual investors, enabling them to tap into opportunities traditionally reserved for institutional players. The company continually enhances its...

Continue Reading
Flux Power Welcomes Kelly Frey as New Chief Revenue Officer

Updated Category News Views 386

Flux Power Appoints New Leadership for Growth Flux Power Holdings, Inc. (NASDAQ: FLUX), a key player in advanced lithium-ion energy storage solutions, has made a significant step towards future growth by appointing Kelly Frey as the Chief Revenue Officer. This strategic move follows the announcement of Tod Kilgore's retirement, effective at the end of January 2025. Mr....

Continue Reading
Ecopetrol's Significant Move: Acquiring Repsol's Stake in CPO-09

Updated Category News Views 142

Ecopetrol's Strategic Acquisition of Repsol's Stake Ecopetrol S.A. (EC), a leading energy company in the region, has announced an agreement with Repsol to purchase their 45% stake in the Exploration and Production Contract for Block CPO-09. This acquisition represents a significant milestone for Ecopetrol, reinforcing its position as a dominant player in the energy...

Continue Reading
ACTEC Welcomes 51 New Members Committed to Excellence

Updated Category News Views 239

ACTEC Expands Its Fellowship with 51 New Members In a momentous decision during a recent meeting, The American College of Trust and Estate Counsel (ACTEC) proudly welcomed 51 new individuals into its prestigious fellowship. The organization, renowned for its commitment to excellence in trust and estate law, highlighted the election of 48 new Fellows, one Academic Fellow,...

Continue Reading